- Home
- INFY vs SNY Comparison
INFY vs SNY Comparison
Compare INFY & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INFY | SNY |
|---|---|---|
| Founded | 1981 | 1994 |
| Country | India | France |
| Employees | N/A | 74846 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.9B | 116.8B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | INFY | SNY |
|---|---|---|
| Price | $14.23 | $46.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $17.20 | ★ $61.50 |
| AVG Volume (30 Days) | ★ 17.6M | 4.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 3.10% | ★ 3.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.31 | $2.62 |
| Revenue Next Year | $7.59 | $6.38 |
| P/E Ratio | $19.11 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.66 | $44.62 |
| 52 Week High | $30.00 | $60.12 |
Technical Indicators
Market Signals| Indicator | INFY | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 43.95 |
| Support Level | $13.92 | $45.20 |
| Resistance Level | $17.56 | $49.01 |
| Average True Range (ATR) | 0.50 | 0.81 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 22.42 | 17.04 |
Price Performance
Historical ComparisonAbout INFY Infosys Limited
Infosys is an IT services provider based in Bengaluru, India, with offices in more than 50 countries. The company leverages its offshore outsourcing model to serve clients across different industries, such as financial services and manufacturing. Infosys' IT services offerings include consulting, digital transformation, and business process outsourcing.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.